Anti-tremor activity of talipexole produced by selective dopamine D2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum

European Journal of Pharmacology

Volumn 319, Issue 2-3, 1997, Pages 197-205

  Kohno, Yasuko ^a   Fukuzaki, Koichiro ^b   Kitahara, Koichi ^b   Koja, Takeshi ^b  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Anti tremor effect; Bromocriptine; Dopamine D2 receptor agonist; Parkinson's disease; Talipexole; Ventromedial tegmentum lesion

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; SULPIRIDE; TALIPEXOLE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; MALE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREMOR;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-AGONISTS; ANIMALS; AZEPINES; BEHAVIOR, ANIMAL; BROMOCRIPTINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; HYPNOTICS AND SEDATIVES; INJECTIONS, SUBCUTANEOUS; LEVODOPA; MACACA FASCICULARIS; MALE; RECEPTORS, DOPAMINE D2; TEGMENTUM MESENCEPHALI; TREMOR;

EID: 0031014879     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00862-X     Document Type: Article

References (18)

1. Goldstein, M., A.F. Battista, T. Ohmoto, B. Anagnoste and K. Fuxe, 1973, Tremor and involuntary movements in monkeys: effects of L-DOPA and of a dopamine receptor stimulating agents, Science 179, 816.
2. Hinzen, D., O. Hornykiewicz, W. Kobinger, L. Pichler, C. Pifl and G. Schignitz, 1986, The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment, Eur. J. Pharmacol. 131, 75.
3. Irifune, M., M. Nomoto and T. Fukuda, 1993, Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets, Eur. J. Pharmacol. 238, 235.
4. Irifune, M., M. Nomoto and T. Fukuda, 1994, Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-DOPA and as chronic treatment, Eur. J. Pharmacol. 264, 117.
5. Kobinger, W. and L. Pichler, 1980, Investigation into different types of post- and presynaptic α-adrenoceptors at cardiovascular sits in rats, Eur. J. Pharmacol. 65, 393.
6. Kohno, Y., S. Shibata, M. Ohno and S. Watanabe, 1996, Electroencephalographic study on sedative effect of talipexole, a novel antiparkinsonian drug, in rats with chronic electrode implants, Pharmacometrics (Oyo Yakuri) 52, 45.
7. 14C]talipexole. (1) Absorption, distribution and excretion after single administration in rats, Iyakuhin Kenkyu 25, 99.
8. 14C]talipexole. (III) Metabolism in rats, Iyakuhin Kenkyu 25, 119.
9. Matsubayashi, H., T. Amano, Y. Hongjing, Y. Kohno and M. Sasa, 1995, Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons, Psychopharmacology 120, 369.
10. 2-receptors after administration of SND 919 in rats, Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 21.
11. Miyamoto, T., A.F. Battista, M. Goldstein and K. Fuxe, 1974, Long-lasting antitremor activity induced by 2-Br-α-ergocriptine in monkeys, J. Pharm. Pharmacol. 26, 452.
12. Nakanishi, T., H. Kowa, Y. Mizuno and N. Yanagisawa, 1993, The clinical evaluation of B-HT 920 (talipexole hydrochloride) in Parkinson's disease - a multi-centered double-blind comparative study vs. bromocriptine mesilate, Clin. Eval. 21, 59.
13. 3 receptor blocking properties of the antiparkinsonian agent, talipexole, Gen. Pharmacol. 27, 779.
14. Ohye, C., S. Imai, H. Nakajima, T. Shibazaki and H. Hirai, 1979, Experimental study of spontaneous postural tremor induced by a more successful tremor-producing procedure in the monkey. Adv. Neurol. 24, 83.
15. Poirier L.J., T.L. Sourkes, G. Bouvier, R. Boucher and S. Carabin, 1966, Striatal amines, experimental tremor and the effect of harmaline in the monkey, Brain 89, 37.
16. 14C]talipexole (IV) - absorption, metabolism and excretion in monkeys, Iyakuhin Kenkyu 25, 134.
17. Szabo, J. and W.M. Cowan, 1984, A stereotaxic atlas of the brain of the cynomolgus monkey, J. Comp. Neurol. 222, 265.
18. Uitti, R.J. and J.E. Ahlskog, 1996, Comparative review of dopamine receptor agonists in Parkinson's disease, CNS Drugs 5, 369.